Commissariat a l'Energie Atomique et aux Energies Alternatives
- Address
- 4 Place Du General Leclerc, 91401 Orsay, France
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The site specializes in cutting‑edge imaging, using 18F‑DPA‑714 PET imaging combined with MRI to enhance diagnostic accuracy and guide surgical decisions for neurological conditions.
- PET‑MRI hybrid imaging
- Neuroinflammation quantification
- Pre‑operative seizure focus localisation
Collaboration with INFLANET supports multicentre studies that aim to refine imaging biomarkers and improve patient selection for advanced therapies.
Nervous System Diseases
Research at the centre targets multiple sclerosis and drug‑resistant epilepsy, seeking to better understand disease mechanisms and optimize treatment pathways.
- White matter lesion assessment in MS
- SEEG‑guided evaluation of surgical candidates
- Neuroinflammatory biomarker development
Efforts led by Service Hospitalier Frederic Joliot aim to translate imaging insights into clearer diagnoses and more effective therapeutic strategies for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Commissariat a l'Energie Atomique et aux Energies Alternatives
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of 18F-DPA-714 PET-MRI for Preoperative Localization in Drug-Resistant Partial Epilepsy Candidates for Surgical Resection | Commissariat a l'Energie Atomique et aux Energies Alternatives | Phase I | Not Recruiting | Nov 2024 | Nov 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide | 2 | Unknown | 2024-11-04 | 2025-12-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.